Loading publications…
The last 5 uploaded publications
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)
Ciara Conduit, Andrisha–Jade Inderjeeth, R.J. Allen, Andrew Martin, Wendy R. Parulekar, Eibhlin Mulroe, Margaret McJannett, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Scott North, Gavin Marx, Anthony M. Joshua, Lisa G. Horvath, Ray McDermott, Simon Chowdhury, Kim N., Alison Y. Zhang, Martin R. Stockler, Ian D. Davis, Christopher J. Sweeney (2025). Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304). , DOI: https://doi.org/10.1080/14796694.2024.2440277.
Article62 days agoFinal Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial
Johann S. de Bono, He Meng, Zhen Shi, Małgorzata Nowicka, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Geng Chen, Nives Selak Bienz, Daniel Canter, Matthew Wongchenko, Christopher J. Sweeney (2025). Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. , DOI: https://doi.org/10.1016/j.eururo.2024.12.015.
Article62 days agoPrognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.
Zahra Sabahi, Nathan Papa, Wolfgang P. Fendler, Andrew Nguyen, Keith Wong, Narjess Ayati, Bao Ho, Jeffrey Chen, Thomas W. Cusick, Irene A. Burger, Megan Crumbaker, Gavin Marx, Shikha Sharma, Mark Frydenberg, Shahneen Sandhu, Ian D. Davis, Martin R. Stockler, Christopher J. Sweeney, Anthony M. Joshua, Louise Emmett (2025). Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5091.
Article62 days agoRadiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304).
Ian D. Davis, Andrew Martin, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John McCaffrey, Ray McDermott, Andrisha Jade Inderjeeth, Lisa G. Horvath, Mark Frydenberg, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher J. Sweeney (2024). Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304).. , 42(4_suppl), DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.151.
Article62 days agoTestosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Christopher J. Sweeney, Andrew Martin, Martin R. Stockler, Stephen Begbie, Leanna Cheung, Kim N., Simon Chowdhury, Mark Frydenberg, Lisa G. Horvath, Anthony M. Joshua, Nicola Jane Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott North, Francis Parnis, Wendy R. Parulekar, David Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott Williams, Diana Winter, Sonia Yip, Alison Y. Zhang, Robert Zielinski, Ian D. Davis, Ehtesham Abdi, Suzanne Allan, Patricia Bastick, Stephen Begbie, Robert Blum, Karen Briscoe, Daniel Brungs, Sean Bydder, Bala Renuka Chittajallu, Michelle R. Cronk, Katharine Cuff, Ian D. Davis, Anthony Dowling, Mark Frydenberg, M. C. George, Lisa G. Horvath, Elizabeth Hovey, Anthony M. Joshua, Narayan Karanth, Ganessan Kichenadasse, Laurence E. Krieger, Gavin Marx, Maitham Mathlum, Louise Nott, Zulfiquer Otty, Francis Parnis, David Pook, Shahneen Sandhu, Sanjeev Sewak, Amanda Gwendolyn Stevanovic, Martin R. Stockler, Aneta Suder, Hsiang Tan, Javier Torres, Simon Troon, Craig Underhill, Andrew Weickhardt, Robert Zielinski, Tahir Abbas, Ghadeer Anan, Chris Booth, H. E. A. Campbell, Kim Chi, Joseph L. Chin, E. Chouinard, Bryan Donnelly, Darrel Drachenberg, Amir Faghih, Antonio Finelli, Sébastien J. Hotte, Krista Noonan, Scott North, Mohammad Rassouli, Neil Reaume, Ricardo Rendon, Fred Saad, Evgeny Sadikov, Éric Vigneault, Paweł Zalewski, John McCaffrey, Ray McDermott, Patrick G. Morris, Miriam O’Connor, Paul Donnellan, Dearbhaile M. O’Donnell, Joanne Edwards, Peter C.C. Fong, Alvin Tan, Simon Chowdhury (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. , 24(4), DOI: https://doi.org/10.1016/s1470-2045(23)00063-3.
Article62 days ago